FDA Again Delays Expanded Use Of Blood Thinner Xarelto

Law360, New York (March 5, 2013, 6:39 PM EST) -- The U.S. Food and Drug Administration has delayed for the second time a decision to expand use of Johnson & Johnson and Bayer AG's blood thinner Xarelto to allow for the treatment of acute coronary syndrome, amid safety concerns over the drug, J&J said Tuesday.

The FDA had sent a response letter to J&J unit Janssen Research & Development LLC, saying it needed answers to a number of unspecified questions related to a trial of the drug before it could consider approving the expansion, according to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.